Count oligo .
Sometimes the decision to treat oligometastatic disease seems to be based on gestalt. Lucky for us there’s plenty of randomized phase 2 data demonstrating survival benefits with ablative radiation for oligomets in the non-small cell lung cancer (NSCLC) space, as nicely outlined in this review article. The problem is, even in this space, the clinical presentation is quite the mixed bag regarding both time course as well as site and burden of disease. One of the most helpful visuals is figure 2 crystallizing which candidates are most likely to benefit from this approach off trial, namely those with low-burden metachronous mets at safely treated target sites. | Jasper, J Clin Oncol 2022